Back to Browse Journals » Clinical Ophthalmology » Volume 1 » Issue 4

Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology

Authors Cleber A Trujillo, Arthur A Nery, Janaí­na M Alves, Antonio H Martins, Henning Ulrich

Published 15 February 2008 Volume 2007:1(4) Pages 393—402

Cleber A Trujillo1, Arthur A Nery1, Janaína M Alves2, Antonio H Martins1, Henning Ulrich1

1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil; 2Departamento de Neurologia Experimental, Universidade Federal de São Paulo, São Paulo, Brazil

Abstract: Age-related macular degeneration (AMD) is the main cause of loss of sight in the world and is characterized by neovascularization of the macula. The factors producing choroidal vascularization involve various growth factors, including the vascular endothelial growth factor (VEGF165). In this context, the systematic evolution of ligands by exponential enrichment (SELEX) became a tool for developing new therapeutic agents for AMD treatment. The SELEX is a combinatorial oligonucleotide library-based in vitro selection approach in which DNA or RNA molecules (aptamers) are identified by their ability to bind their targets with high affinity and specificity. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands for a wide range of proteins of clinical importance. For instance, Pegaptanib sodium, a 28-nucleotide polyethylene glycol RNA aptamer that selectively binds to VEGF165 and inhibits angiogenesis, was approved by the Food and Drug Administration for the treatment of wet AMD, thereby providing significant benefits to a great number of patients with minimal adverse effects.

Keyword: anti-VEGF aptamer, pegaptanib, age-related macular degeneration

Download Article [PDF] 

Readers of this article also read:

Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells

Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ

International Journal of Nanomedicine 2012, 7:4973-4982

Published Date: 14 September 2012

Corrigendum

Kukulka M, Eisenberg C, Nudurupati S

Clinical and Experimental Gastroenterology 2011, 4:255-256

Published Date: 14 October 2011

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Vascular Health and Risk Management 2010, 6:671-690

Published Date: 5 August 2010

Clinical experience with pegaptanib sodium

Chiara Rosina, Ferdinando Bottoni, Giovanni Staurenghi

Clinical Ophthalmology 2008, 2:485-488

Published Date: 12 September 2008

SUNCT syndrome: The materialization of a headache syndrome

Ottar Sjaastad

Clinical Ophthalmology 2008, 2:533-543

Published Date: 12 September 2008

The renin–angiotensin system and diabetes: An update

Antônio Ribeiro-Oliveira Jr, Anelise Impeliziere Nogueira, Regina Maria Pereira, Walkiria Wingester Vilas Boas, Robson Augusto Souza dos Santos, Ana Cristina Simões e Silva

Vascular Health and Risk Management 2008, 4:787-803

Published Date: 8 August 2008

The interleukin-6 –174 G/C promoter polymorphism and arterial stiffness; the Rotterdam Study

Mark PS Sie, Francesco US Mattace-Raso, André G Uitterlinden, Pascal P Arp, Albert Hofman, et al

Vascular Health and Risk Management 2008, 4:863-869

Published Date: 8 August 2008

The challenge of dry eye diagnosis

Giacomo Savini, Pinita Prabhawasat, Takashi Kojima, Martin Grueterich, Edgar Espana, Eiki Goto

Clinical Ophthalmology 2008, 2:31-55

Published Date: 7 March 2008

A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery

Helga P Sandoval, Luis E Fernández de Castro, David T Vroman, Kerry D Solomon

Clinical Ophthalmology 2007, 1:367-371

Published Date: 15 February 2008

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

Baptist Gallwitz

Vascular Health and Risk Management 2007, 3:203-210

Published Date: 15 May 2007